| Not Yet Recruiting | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab NCT04266730 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Not Yet Recruiting | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy NCT07360132 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Smal NCT07221474 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ So NCT07169734 | Alentis Therapeutics AG | Phase 1 / Phase 2 |
| Withdrawn | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamo NCT05879484 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585 | Alentis Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer NCT05902988 | Volastra Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NCT06307093 | R-Pharm | Phase 1 |
| Terminated | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cance NCT05275673 | Faeth Therapeutics | Phase 2 |
| Unknown | A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC NCT04976647 | Shanghai Henlius Biotech | Phase 2 |
| Unknown | Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCL NCT05243355 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Maligna NCT05123482 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer NCT04736173 | Arcus Biosciences, Inc. | Phase 2 |
| Terminated | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer NCT04432207 | Imugene Limited | Phase 1 |
| Unknown | KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer NCT04474119 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 |
| Completed | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Ce NCT04262856 | Arcus Biosciences, Inc. | Phase 2 |
| Completed | A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilot NCT04552535 | Boehringer Ingelheim | — |
| Unknown | Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell L NCT04073537 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Unknown | A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Lin NCT04033354 | Shanghai Henlius Biotech | Phase 3 |
| Unknown | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancie NCT04149691 | Celon Pharma SA | Phase 1 |
| Withdrawn | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous NCT03319316 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC NCT03717155 | Merck KGaA, Darmstadt, Germany | Phase 2 |
| Unknown | Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cance NCT03542461 | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 |
| Completed | A Study to Assess the Efficacy and Safety of ABTL0812 NCT03366480 | Ability Pharmaceuticals SL | Phase 1 / Phase 2 |
| Withdrawn | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lu NCT02924233 | Symphogen A/S | Phase 1 / Phase 2 |
| Unknown | Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU) NCT02996214 | Nanjing Luye Sike Pharmaceutical Co., Ltd. | Phase 4 |
| Completed | A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared NCT02367794 | Hoffmann-La Roche | Phase 3 |
| Terminated | AZD2014 and Weekly Paclitaxel in Squamous NSCLC NCT02403895 | AstraZeneca | Phase 2 |
| Terminated | A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or M NCT02204345 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Pr NCT02106546 | AbbVie | Phase 3 |
| Terminated | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advan NCT02109016 | Clovis Oncology, Inc. | Phase 2 |
| Terminated | Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT01911325 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) NCT01763788 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer NCT01769391 | Eli Lilly and Company | Phase 2 |
| No Longer Available | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC Aft NCT02475382 | Bristol-Myers Squibb | — |